Resultados de la búsqueda 131-140 of 2455 for Albicans

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this research trail is to study the genetic alteration/mutation and immune profiling in surgical resected Non-small Cell Lung Cancer (NSCLC) ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma ...

  5. Hematología - Ensayos clínicos - Mayo Clinic

    Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  8. Hematología - Ensayos clínicos - Mayo Clinic

    Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients ...

  9. Prophylactic Table ID File.indd

    Page 1.

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...